Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dapagliflozin vs Pharmacist Intervention in T2DM
NCT06719661Completed
- Sponsor
- University of Sulaimani
- Start
- Dec 2024
- Primary completion
- May 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of dapagliflozin in type 2 diabetes mellitus (T2DM) (3 arms), sponsored by University of Sulaimani. Primary endpoints: Hemoglobin A1c at 3 months, Fasting Plasma Glucose at 3 months and 3 more. Started Dec 2024; status: completed.
02
Drugs
dapagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT06719661.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06719661.